Targeting survivin in cancer

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 225-228

  Altieri, Dario C ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Antisense; Cancer therapy; IAP; Signaling networks; Small molecule; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; ENZ 3042; GATAPARSEN; SEPANTRONIUM BROMIDE; SURVIVIN; TERAMEPROCOL; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

EID: 84876096250     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.005     Document Type: Review

References (65)

1. Lens S.M., Vader G., Medema R.H. The case for survivin as mitotic regulator. Curr. Opin. Cell Biol. 2006, 18:616-622.
2. Li F., Brattain M.G. Role of the survivin gene in pathophysiology. Am. J. Pathol. 2006, 169:1-11.
3. Kotwaliwale C., Biggins S. Microtubule capture: a concerted effort. Cell 2006, 127:1105-1108.
4. Stauber R.H., Mann W., Knauer S.K. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007, 67:5999-6002.
5. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009.
6. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
7. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14:5000-5005.
8. Srinivasula S.M., Ashwell J.D. IAPs: what's in a name?. Mol. Cell 2008, 30:123-135.
9. Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E. Structure of a survivin-borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 2007, 131:271-285.
10. Guha M., Altieri D.C. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 2009, 8:2708-2710.
11. Ruchaud S., Carmena M., Earnshaw W.C. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol. 2007, 8:798-812.
12. Sampath S.C., Ohi R., Leismann O., Salic A., Pozniakovski A., Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell 2004, 118:187-202.
13. Rosa J., Canovas P., Islam A., Altieri D.C., Doxsey S.J. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol. Biol. Cell 2006, 17:1483-1493.
14. Sandall S., Severin F., McLeod I.X., Yates J.R., Oegema K., Hyman A., Desai A. A Bir1-Sli15 complex connects centromeres to microtubules and is required to sense kinetochore tension. Cell 2006, 127:1179-1191.
15. Dohi T., Xia F., Altieri D.C. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol. Cell 2007, 27:17-28.
16. Song Z., Yao X., Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J. Biol. Chem. 2003, 278:23130-23140.
17. Ceballos-Cancino G., Espinosa M., Maldonado V., Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 2007, 26:7569-7575.
18. Kang B.H., Altieri D.C. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J. Biol. Chem. 2006, 281:24721-24727.
19. Ghosh J.C., Dohi T., Kang B.H., Altieri D.C. Hsp60 regulation of tumor cell apoptosis. J. Biol. Chem. 2008, 283:5188-5194.
20. Fortugno P., Beltrami E., Plescia J., Fontana J., Pradhan D., Marchisio P.C., Sessa W.C., Altieri D.C. Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 2003, 100:13791-13796.
21. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351:2817-2826.
22. van der Greef J., McBurney R.N. Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discovery 2005, 4:961-967.
23. Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., Villa A., Marchisio P.C., Altieri D.C. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1999, 1:461-466.
24. Molckovsky A., Siu L.L. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American Society of Clinical Oncology meeting. J. Hematol. Oncol. 2008, 1:20.
25. Hansen J.B., Fisker N., Westergaard M., Kjaerulff L.S., Hansen H.F., Thrue C.A., Rosenbohm C., Wissenbach M., Orum H., Koch T. SPC3042: a proapoptotic survivin inhibitor. Mol. Cancer Ther. 2008, 7:2736-2745.
26. Walker K., Padhiar M. AACR-NCI-EORTC - 21st international symposium. Molecular targets and cancer therapeutics - Part 1. IDrugs 2010, 13:7-9.
27. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets 2008, 12:463-476.
28. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
29. Nakahara T., Takeuchi M., Kinoyama I., Minematsu T., Shirasuna K., Matsuhisa A., Kita A., Tominaga F., Yamanaka K., Kudoh M., Sasamata M. YM155, a Novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007, 67:8014-8021.
30. Tolcher A.W., Mita A., Lewis L.D., Garrett C.R., Till E., Daud A.I., Patnaik A., Papadopoulos K., Takimoto C., Bartels P., Keating A., Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 2008, 26:5198-5203.
31. Satoh T., Okamoto I., Miyazaki M., Morinaga R., Tsuya A., Hasegawa Y., Terashima M., Ueda S., Fukuoka M., Ariyoshi Y., Saito T., Masuda N., Watanabe H., Taguchi T., Kakihara T., Aoyama Y., Hashimoto Y., Nakagawa K. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:3872-3880.
32. Giaccone G., Zatloukal P., Roubec J., Floor K., Musil J., Kuta M., van Klaveren R.J., Chaudhary S., Gunther A., Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:4481-4486.
33. K.D. Lewis, W. Samlowski, J. Ward, J. Catlett, L. Cranmer, J. Kirkwood, D. Lawson, E. Whitman, R. Gonzalez, A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma, Invest. New Drugs (2009) (Epub Ahead of Print October15).
34. Chang C.C., Heller J.D., Kuo J., Huang R.C. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc. Natl. Acad. Sci. USA 2004, 101:13239-13244.
35. Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 2008, 11:204-214.
36. Park R., Chang C.C., Liang Y.C., Chung Y., Henry R.A., Lin E., Mold D.E., Huang R.C. Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Clin. Cancer Res. 2005, 11:4601-4609.
37. Zhu X., Ma Y., Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J. Hematol. Oncol. 2010, 3:17.
38. Khanna N., Dalby R., Connor A., Church A., Stern J., Frazer N. Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers. Sex. Transm. Dis. 2008, 35:577-582.
39. Khanna N., Dalby R., Tan M., Arnold S., Stern J., Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol. 2007, 107:554-562.
40. Andersen M.H., Sorensen R.B., Schrama D., Svane I.M., Becker J.C., Thor Straten P. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol. Immunother. 2008.
41. Rohayem J., Diestelkoetter P., Weigle B., Oehmichen A., Schmitz M., Mehlhorn J., Conrad K., Rieber E.P. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 2000, 60:1815-1817.
42. Schmidt S.M., Schag K., Muller M.R., Weck M.M., Appel S., Kanz L., Grunebach F., Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003, 102:571-576.
43. Casati C., Dalerba P., Rivoltini L., Gallino G., Deho P., Rini F., Belli F., Mezzanzanica D., Costa A., Andreola S., Leo E., Parmiani G., Castelli C. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res. 2003, 63:4507-4515.
44. Idenoue S., Hirohashi Y., Torigoe T., Sato Y., Tamura Y., Hariu H., Yamamoto M., Kurotaki T., Tsuruma T., Asanuma H., Kanaseki T., Ikeda H., Kashiwagi K., Okazaki M., Sasaki K., Sato T., Ohmura T., Hata F., Yamaguchi K., Hirata K., Sato N. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin. Cancer Res. 2005, 11:1474-1482.
45. Schmitz M., Diestelkoetter P., Weigle B., Schmachtenberg F., Stevanovic S., Ockert D., Rammensee H.G., Rieber E.P. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000, 60:4845-4849.
46. Pisarev V., Yu B., Salup R., Sherman S., Altieri D.C., Gabrilovich D.I. Full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res. 2003, 9:6523-6533.
47. Siegel S., Wagner A., Schmitz N., Zeis M. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br. J. Haematol. 2003, 122:911-914.
48. Friedrichs B., Siegel S., Andersen M.H., Schmitz N., Zeis M. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk. Lymphoma 2006, 47:978-985.
49. R. Trepiakas, A. Berntsen, S.R. Hadrup, J. Bjorn, P.F. Geertsen, P.T. Straten, M.H. Andersen, A.E. Pedersen, A. Soleimani, T. Lorentzen, J.S. Johansen, I.M. Svane, Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial, Cytotherapy (2010) (Epub ahead of Print April 29).
50. Berntsen A., Trepiakas R., Wenandy L., Geertsen P.F., thor Straten P., Andersen M.H., Pedersen A.E., Claesson M.H., Lorentzen T., Johansen J.S., Svane I.M. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J. Immunother. 2008, 31:771-780.
51. Weide B., Pascolo S., Scheel B., Derhovanessian E., Pflugfelder A., Eigentler T.K., Pawelec G., Hoerr I., Rammensee H.G., Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 2009, 32:498-507.
52. Wobser M., Keikavoussi P., Kunzmann V., Weininger M., Andersen M.H., Becker J.C. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 2006, 55:1294-1298.
53. Kamb A., Wee S., Lengauer C. Why is cancer drug discovery so difficult?. Nat. Rev. Drug Discovery 2007, 6:115-120.
54. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 2006, 5:1087-1098.
55. Blum B., Bar-Nur O., Golan-Lev T., Benvenisty N. The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat. Biotechnol. 2009, 27:281-287.
56. Weinstein I.B., Joe A.K. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 2006, 3:448-457.
57. O'Connor D.S., Wall N.R., Porter A.C., Altieri D.C. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002, 2:43-54.
58. Lee C.W., Raskett C.M., Prudovsky I., Altieri D.C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008, 68:5273-5281.
59. Kim P.J., Plescia J., Clevers H., Fearon E.R., Altieri D.C. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362:205-209.
60. O'Connor D.S., Schechner J.S., Adida C., Mesri M., Rothermel A.L., Li F., Nath A.K., Pober J.S., Altieri D.C. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 2000, 156:393-398.
61. Daly C., Wong V., Burova E., Wei Y., Zabski S., Griffiths J., Lai K.M., Lin H.C., Ioffe E., Yancopoulos G.D., Rudge J.S. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev. 2004, 18:1060-1071.
62. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA 2002, 99:4349-4354.
63. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discovery 2008, 7:989-1000.
64. Plescia J., Salz W., Xia F., Pennati M., Zaffaroni N., Daidone M.G., Meli M., Dohi T., Fortugno P., Nefedova Y., Gabrilovich D.I., Colombo G., Altieri D.C. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7:457-468.
65. Sun C., Nettesheim D., Liu Z., Olejniczak E.T. Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry 2005, 44:11-17.